EGFR and neoplasm: A meta-analysis (28) including the CheckMate 057, KEYNOTE 010 and POPLAR trials indicated that PD-1/PD-L1 inhibitors alone did not show superior survival over docetaxel in patients with tumor EGFR mutations.